Which biologic works best first for ulcerative colitis? major trial aims to find out

NCT ID NCT07576452

Not yet recruiting Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares four different sequences of biologic drugs (infliximab, filgotinib, ustekinumab, and vedolizumab) in 240 adults with moderate to severe ulcerative colitis. The goal is to see which order of treatments works best to achieve and maintain remission without steroids. Participants will be followed for two years with regular check-ups and endoscopies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab, filgotinib, ustekinumab, vedolizumab
What this could lead to: If successful, this study could identify the best order of biologic treatments for ulcerative colitis, improving remission rates and quality of life.
What could go wrong: This is a Phase 4 trial comparing existing drugs, so no new treatment is being discovered. Results may not apply to all patients, and individual responses can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.